Juli Warwicker PhD

Senior Protein Scientist

Juli has significant experience in molecular biology, cell culture, protein purification and analysis gained from over 20 years in the pharmaceutical and biotech sector.

Juli Warwicker PhD Protein Purification Specialist

More about Juli

Juli has 15 years experience working in the pharmaceutical industry, specialising in the supply of recombinant proteins and validated tool antibodies to support drug discovery projects, from target validation through to clinical trials.

Immediately before joining Peak Proteins Juli worked at AstraZeneca for 15 years, based in Reagent Supply teams. Prior to working at AstraZeneca, she spent several years in academia and government science, researching membrane lipases and storage proteins.

Generating Selective Leads for Mer Kinase Inhibitors-Example of a Comprehensive Lead-Generation Strategy.
J Med Chem. 2021 Mar 25;64(6): 3165-3184.
Nissink JWM, Bazzaz S, Blackett C, Clark MA, Collingwood O, Disch JS, Gikunju D, Goldberg K, Guilinger JP, Hardaker E, Hennessy EJ, Jetson R, Keefe AD, McCoull W, McMurray L, Olszewski A, Overman R, Pflug A, Preston M, Rawlins PB, Rivers E, Schimpl M, Smith P, Truman C, Underwood E, Warwicker J, Winter-Holt J, Woodcock S and Zhang Y.

A-loop interactions in Mer tyrosine kinase give rise to inhibitors with two-step mechanism and long residence time of binding.
Biochem J. 2020 Nov 27; 477(22): 4443–4452..
Alexander Pflug, Marianne Schimpl, J. Willem M. Nissink, Ross C. Overman, Philip B. Rawlins, Caroline Truman, Elizabeth Underwood, Juli Warwicker, Jon Winter-Holt, and William McCoull

Tool inhibitors and assays to interrogate the biology of the TRAF2 and NCK interacting kinase
Bioorganic & Medicinal Chemistry Letters. 2019 Aug 1;29(15):1962-1967
Read J, Collie IT, Nguyen-McCarty M, Lucaj C, Robinson J, Conway L, Mukherjee J, McCall E, Donohoe G, Flavell E, Peciak K, Warwicker J, Dix C, Van den Hoven BG, Madin A, Brown DG, Moss S, Haggarty SJ, Brandon NJ and Bürli RW.

Heparan sulfates are critical regulators of the inhibitory megakaryocyte-platelet receptor G6b-B
Elife. 2019 8. pii: e46840
Vögtle T, Sharma S, Mori J, Nagy Z, Semeniak D, Scandola C, Geer MJ, Smith CW, Lane J, Pollack S, Lassila R, Jouppila A, Barr AJ, Ogg DJ, Howard TD, McMiken HJ, Warwicker J, Geh C, Rowlinson R, Abbott WM, Eckly A, Schulze H, Wright GJ, Mazharian A, Fütterer K, Rajesh S, Douglas MR, Senis YA.

The Use of Antibodies in Small-Molecule Drug Discovery
J. Biomol. Screen 201419 829-38.
Marsden CJ, Eckersley S, Hebditch, M, Kvist, AJ, Milner R, Mitchell D, Warwicker J, Marely A.

Validation of BRCA1 antibody MS 110 and the utility of BRCA1as a patient selction biomarker in immunohistological analysis of breast and ovarian tumours
Virchows Arch. 2013, 462 269-79.
Milner R, Wombwell H, Eckersley S, Barnes D, Warwicker J, Van drop E, Rowlinson R, Dearden S, Hughes G, Harbron C, Wellings B, Hodgson D, Womack C, Gary N, Lau A, O’Conor MJ, Marsden CJ, & Kvist, AJ.